Accuray Appoints New Chief Commercial Officer
Accuray Incorporated, a leading provider of radiation therapy systems for cancer treatment, has appointed Paul Miele as its new Senior Vice President and Chief Commercial Officer. Miele will lead the company's global commercial strategy, sales operations, and go-to-market initiatives, aiming to accelerate the adoption of Accuray's radiation therapy solutions worldwide. This appointment underscores Accuray's focus on strengthening its commercial capabilities and driving growth in the competitive medical technology sector.
Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer Effective April 6, 2026 11
Accuray Incorporated (NASDAQ: ARAY) has appointed Paul Miele as its new Senior Vice President and Chief Commercial Officer, effective April 6, 2026. This strategic move aims to strengthen the company's commercial leadership, drive revenue growth, and expand market presence. Investors are advised to monitor future communications for details on Mr. Miele's plans and the potential impact on Accuray's financial performance.
Accuray Names Paul Miele Chief Commercial Officer
Accuray has appointed Paul Miele as Senior Vice President and Chief Commercial Officer to enhance its global commercial execution and support long-term growth in radiation therapy markets. Miele brings nearly two decades of experience in scaling capital equipment businesses, aiming to boost sales and monetize Accuray's installed base. Spark, TipRanks' AI Analyst, rates ARAY as Neutral due to weak financial quality, declining revenue, and high leverage, despite positive demand indicators.
Accuray names Paul Miele as chief commercial officer
Accuray Incorporated (NASDAQ:ARAY) has appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective today. Miele, with two decades of experience in global medical device businesses, will lead Accuray's commercial organization, focusing on sales, marketing, pricing, and strategic partnerships. This announcement follows Accuray's recent financial results, which showed a revenue decline and a Nasdaq listing notice due to non-compliance with the minimum bid price rule, despite an InvestingPro analysis suggesting the stock is undervalued.
Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
Accuray Incorporated announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele brings extensive global commercial leadership experience from his previous roles at Johnson & Johnson MedTech, Globus Medical, and Intuitive Surgical. He will lead Accuray's global commercial organization, focusing on driving sales growth and strengthening commercial performance for the cancer treatment systems provider.
New Accuray (NASDAQ: ARAY) CCO to lead global commercial strategy
Accuray Incorporated has appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will lead the company’s global commercial organization across sales, marketing, pricing, and market access, aiming to strengthen commercial execution and drive systems and services sales growth. This appointment, disclosed in an 8-K filing, is part of Accuray's ongoing transformation to enhance long-term value creation, leveraging Miele's experience in driving commercial turnarounds within complex medical technology businesses.
Accuray recruits J&J MedTech executive to run global sales
Accuray (NASDAQ: ARAY) has appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele, previously with Johnson & Johnson MedTech, will lead Accuray's global commercial strategy, aiming to improve sales execution and drive growth. His background includes a proven track record of reversing revenue declines and achieving double-digit sales growth in medical technology businesses.
Accuray (ARAY) SVP Chalke uses 40,000 shares to cover RSU taxes
Accuray Inc. SVP and Chief Commercial Officer Sandeep Chalke had 40,000 shares of common stock withheld by the company. This action was taken to cover tax obligations arising from the vesting of Restricted Stock Units (RSUs) at an implied price of $0.3881 per share. Following this transaction, Chalke directly holds 419,806 shares of Accuray Inc.
Q1 2026 Accuray Inc Earnings Call Transcript
This article provides the edited transcript of Accuray Inc.'s Q1 2026 earnings call. It highlights key positive developments such as the launch of the Stellar product, a 7% increase in service revenue, and a strong order backlog. Conversely, it also addresses negative aspects including a 7% decline in net revenue, a 23% decrease in product revenue, and a significant operating loss and negative adjusted EBITDA for the quarter.
Vanguard (ARAY) amendment shows 0 shares after internal realignment
Vanguard has filed an amendment (Schedule 13G/A) for Accuray Inc (ARAY), reporting 0 shares and 0% beneficial ownership as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, where Vanguard's subsidiaries and business divisions will now report beneficial ownership separately, in accordance with SEC Release No. 34-39538. Vanguard explicitly states it no longer holds beneficial ownership over the securities managed by these disaggregated entities.
If You Invested $1,000 in Accuray Incorp (ARAY)
This article analyzes the historical performance of a $1,000 investment in Accuray Incorp (ARAY) over 1, 5, and 10 years, showing significant losses and underperformance compared to the S&P 500. It also provides an overview of Accuray Incorporated, detailing its radiation oncology solutions, key technologies like CyberKnife and Radixact, strategic transformation, financial reporting, and positioning within the radiation oncology industry.
ARAY SEC Filings - Accuray Incorp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Accuray Incorporated (ARAY) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms (Form 4). It highlights how these documents provide insights into the company's financial performance, governance, and key corporate events, with AI-powered summaries to help users quickly grasp the significance of each filing. Recent filings cover topics such as director ownership, quarterly financial results, executive compensation, and equity grants.
Accuray (NASDAQ: ARAY) sets separation terms for chief commercial officer
Accuray Incorporated has finalized a separation agreement with its Senior Vice President and Chief Commercial Officer, Sandeep Chalke, ahead of his March 31, 2026 departure. The agreement includes the vesting of equity awards due on May 31, 2026, a lump-sum cash payment of $459,000, and a pro-rated fiscal 2026 bonus. This arrangement replaces previous severance terms and includes a general release of claims.
Book value per share of Accuray Incorporated – BX:XEJ
This article displays the book value per share for Accuray Incorporated (BX:XEJ). It is a financial data point available on TradingView, with specific values for different periods. The article confirms that the market for this particular stock is currently closed.
Accuray (NASDAQ: ARAY) COO exercises RSUs, uses shares to cover tax
Accuray's SVP and COO, Leonel Peralta, exercised 83,723 restricted stock units on February 28, 2026, receiving common shares at $0.00 each. To cover tax withholding obligations, 28,969 common shares were withheld by the company at $0.55 per share. Following these transactions, Peralta directly owns 54,754 shares of Accuray common stock.
ACCURAY INC SEC Filing - Form EFFECT
ACCURAY INC (ARAY) has filed an EFFECT form with the SEC, indicating the effectiveness of its S-3 Shelf Registration Statement as of February 27, 2026, at 9:00 A.M. This filing is deemed neutral in both impact and sentiment by Rhea-AI. The company's recent news includes reporting Q2 2026 financial results and announcing a strategic transformation plan.
7.00M shares registered for resale as ARAY (NASDAQ: ARAY) lenders hold warrants
Accuray Incorporated (NASDAQ: ARAY) has filed a prospectus registering 7,000,516 shares of common stock for resale by existing stockholders. These shares are issuable upon the exercise of warrants that were previously issued to lenders as part of a Loan Amendment. Accuray will not receive proceeds from the resale of these shares but will benefit from any cash exercise of the warrants.
ARAY Technical Analysis & Stock Price Forecast
Accuray Inc (ARAY) is currently exhibiting a "Strong Sell" technical sentiment based on an analysis of 11 technical signals, with 1 indicating buy and 10 indicating sell. The stock is trading below its 60-day and 200-day moving averages, and key indicators like MACD also suggest a sell signal. While the RSI is neutral, the overall technical outlook points to bearish momentum for ARAY.
Accuray (ARAY) files S-3 to register 7.0M warrant shares for lender resale
Accuray Inc. (ARAY) has filed an S-3 registration statement to allow certain lending investors to resell 7,000,516 shares of common stock. These shares are issuable upon the exercise of Super Premium, Premium, and Penny Warrants, previously granted in connection with an amendment to Accuray's senior secured Financing Agreement. Accuray will not receive proceeds from the resale of these shares, but would receive cash if the warrant holders choose to exercise them for cash.
Accuray partners with Limbus AI on adaptive radiotherapy
Accuray has partnered with Limbus AI to augment its adaptive radiotherapy capabilities by integrating Limbus AI's AI-driven auto contouring algorithms. This collaboration aims to streamline the treatment planning process, specifically by automating the critical and time-consuming step of defining tumor borders and organs at risk. This integrated offering is expected to be available in 2023, enhancing efficiency and enabling more personalized patient care with Accuray's existing technologies.
Accuray (NASDAQ: ARAY) furnishes fiscal 2026 Q2 earnings call presentation
Accuray (NASDAQ: ARAY) has filed an 8-K report announcing the furnishing of an updated investor presentation related to its fiscal 2026 second quarter earnings call. This presentation is available on the company's Investor Relations website and as Exhibit 99.1 to the 8-K filing. It will be used in discussions with analysts and investors on or after February 17, 2026, and provides summary information to be considered alongside the company's other SEC filings.
Accuray Warned by Nasdaq Over Sub‑$1 Share Price, Faces Rising Delisting and Liquidity Risks
Accuray Incorporated (ARAY) has received a notice from Nasdaq on February 2, 2026, due to its stock trading below the $1.00 minimum bid price for 30 consecutive business days, creating a heightened listing risk. The company has been granted an initial 180-day compliance period, with a possibility of an extension, but faces potential delisting if it fails to meet Nasdaq's standards. Delisting could lead to reduced liquidity, depressed stock prices, and difficulty in raising capital.
Accuray (ARAY) Plans to Sell 7 Million Shares of Common Stock
Accuray Inc (ARAY) has announced its intention to offer 7 million shares of its common stock for sale, allowing existing shareholders to divest their holdings. The company, which specializes in advanced radiation therapy systems like the CyberKnife, faces financial challenges including a negative EPS, high leverage, and declining margins, with an Altman Z-Score indicating potential bankruptcy risk. Investors are closely watching the market's response to this offering and the stock's future performance.
Accuray posts updated investor presentation, to present to analysts and investors
Accuray has published an updated investor presentation on its investor relations website, as disclosed in a Form 8-K filing on February 17, 2026. Company representatives are scheduled to present these contents to analysts and investors on or after the same date. The presentation, which includes forward-looking statements, provides summary information about the company.
ACCURAY INC SEC 10-Q Report
Accuray Inc. has released its Q2 FY2026 10-Q report, detailing significant financial and operational challenges. The report shows declines in revenue and profitability, impacted by increased costs, lower product sales, and macroeconomic factors like geopolitical tensions affecting the China region. The company expects continued challenges through fiscal year 2026.
Accuray Inc Announces Resignation of Chief Commercial Officer
Accuray Inc (ARAY) announced the resignation of Sandeep Chalke, Senior Vice President and Chief Commercial Officer, effective March 31, 2026. The company stated that his resignation is not due to any disagreement with the company. Details regarding his replacement were not disclosed.
Accuray Delays Quarterly Filing After Disclosure Review
Accuray (ARAY) has announced a delay in filing its Form 10-Q for the quarter ended December 31, 2025, due to errors found in its remaining performance obligations disclosure from previous filings. The company expects to submit the report within a five-day extension and states that these errors are not anticipated to affect its Balance Sheets, Statements of Operations, or Cash Flows. Accuray also notes that this is a one-off issue and does not foresee a significant change in its operational results compared to the prior year.
Accuray (NASDAQ:ARAY) Cut to "Sell" at Wall Street Zen
Wall Street Zen downgraded Accuray (NASDAQ:ARAY) from "hold" to "sell" on Saturday, February 7, 2026, contributing to a MarketBeat consensus rating of "Hold" with an average price target of $2.00. The company reported quarterly EPS of ($0.11), meeting estimates, and revenue of $102.24 million, but continues to show negative net margins and strained profitability. Despite institutional investment, shares opened at $0.62, currently trading with a market cap of approximately $70.27 million.
Accuray Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Accuray (ARAY) received a notice from Nasdaq on February 2, 2026, indicating non-compliance with the minimum $1.00 bid price rule, as its stock traded below this threshold for 30 consecutive business days. The company has 180 days, until August 3, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. An additional 180-day period may be granted if Accuray transfers to the Nasdaq Capital Market.
The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%
Accuray Incorporated's share price has fallen 33% in the last month, contributing to a 78% decline over the past year. The company's low price-to-sales (P/S) ratio of 0.2x, significantly below the industry average, is attributed to recent revenue declines and a projected future growth of only 3.8% compared to the industry's 53%. Investors appear wary of the company's limited growth prospects, reflecting in its suppressed stock valuation.
Accuray Incorporated 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ARAY) 2026-02-05
Accuray Incorporated (NASDAQ:ARAY) published its Q2 2026 earnings call presentation, reporting an EPS of -$0.11 which beat expectations by $0.00, and revenue of $102.24M, exceeding estimates by $1.38M despite an 11.99% year-over-year decrease. The article highlights the availability of the slide deck from the earnings call.
Accuray Incorporated (NASDAQ:ARAY) Q2 2026 Earnings Call Transcript
Accuray Incorporated reported its Q2 2026 earnings, missing expectations with an EPS of $-0.11 against an expectation of $-0.02. The company announced a comprehensive strategic transformation plan targeting a $25 million improvement in annualized operating profitability, including a 15% workforce reduction. Due to ongoing tariffs and geopolitical instability, particularly in China, the company reduced its fiscal 2026 revenue guidance to $440 million - $450 million and adjusted EBITDA guidance to $22 million - $25 million.
Accuray cuts 15% of staff in $25M overhaul while swinging to loss
Accuray (NASDAQ: ARAY) reported a 12% revenue decline to $102.2 million and a net loss of $13.8 million for Q2 fiscal 2026. In response, the company is implementing a transformation plan, including a 15% workforce reduction, aiming for a $25 million annualized operating profit improvement. Accuray also updated its FY2026 guidance, projecting $440-$450 million in revenue and $22-$25 million in adjusted EBITDA.
Accuray Incorporated (NASDAQ:ARAY) Plunges Over 13% on Weak Guidance Despite Narrow Earnings Beat
Accuray Incorporated (NASDAQ:ARAY) experienced a significant over 13% drop in after-hours trading despite a narrow earnings beat for its fiscal Q2 2026. The market reacted negatively primarily due to weak guidance for future quarters, indicating that investors are more concerned with the company's forward-looking prospects and operational challenges than its past performance. This sharp decline underscores investor skepticism about Accuray's ability to meet future targets for growth and profitability.
Earnings call transcript: Accuray’s Q2 2026 results show revenue dip, stock steady
Accuray Incorporated reported a revenue dip in Q2 2026, reaching $102.2 million against a forecast of $109.11 million, though its EPS of -$0.11 matched expectations. The company's stock remained stable in after-hours trading, reflecting market confidence despite a 12% year-over-year decline in revenue, primarily due to product revenue decreases and geopolitical tensions in China. Accuray has lowered its full-year 2026 revenue guidance to $440-$450 million and is undergoing operational restructuring, including a 15% workforce reduction, to improve profitability and focus on sustainable growth.
Accuray: Fiscal Second Quarter Earnings Overview
Accuray Inc. reported a net loss of $13.8 million, or 11 cents per share, for its fiscal second quarter, a decline compared to a profit in the same period last year. The radiation oncology solutions company generated $102.2 million in revenue. Share value significantly decreased from $2.33 a year prior to 76 cents by the close of trading on Wednesday.
Accuray: Fiscal Second Quarter Earnings Overview
Accuray Inc. reported a net loss of $13.8 million for its fiscal second quarter, equating to 11 cents per share, a decline from a profit in the prior year. The radiation oncology solutions company generated $102.2 million in revenue during this period. Accuray's stock price also saw a significant drop, trading at 76 cents per share compared to $2.33 a year ago.
Accuray earnings matched, revenue fell short of estimates
Accuray (NASDAQ: ARAY) reported second-quarter earnings per share (EPS) of $-0.110, which matched analyst estimates, but its revenue of $102.2 million fell short of the consensus estimate of $109.11 million. The company's guidance for fiscal year 2026 revenue is $440 million to $450 million, below the analyst consensus of $466.7 million. Accuray's stock has seen a significant decline over the last 3 and 12 months, and its financial health is rated as "fair performance."
Accuray Posts Weaker Q2 Results Amid Ongoing Transformation
Accuray (ARAY) reported significantly weaker fiscal Q2 2026 results, with revenue declining 12% year-on-year to $102.2 million and the company swinging to a $13.8 million net loss. In response, Accuray has initiated a major transformation, including staff reductions of about 15% and cost-cutting measures, aiming for $25 million in annualized operating profit improvements. Despite a reaffirmation of strategic goals and updated full-year guidance, the financial performance and market conditions present considerable challenges for the medical technology company.
Accuray: Fiscal Q2 Earnings Snapshot
Accuray Inc. (ARAY) reported a fiscal second-quarter loss of $13.8 million, or 11 cents per share, which contrasts with a profit in the same period last year. The radiation oncology company posted revenue of $102.2 million for the quarter. Its shares were trading at 66 cents, down from $2.35 a year ago.
Vanguard discloses 5.13% Accuray (ARAY) holding in Schedule 13G
The Vanguard Group has filed a Schedule 13G, disclosing a 5.13% beneficial ownership stake in Accuray Inc. (ARAY) common stock, totaling 5,818,576 shares as of December 31, 2025. Vanguard states these holdings are in the ordinary course of business and not intended to influence control of Accuray. An internal realignment effective January 12, 2026, will lead to certain subsidiaries reporting beneficial ownership separately in the future.
Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026
Accuray Incorporated (NASDAQ: ARAY) will announce its financial results for the second quarter of fiscal year 2026, which ended on December 31, 2025, during a conference call on February 4, 2026, at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the call via dial-in numbers or a live webcast on the company's investor relations website, with replays available afterward. Accuray focuses on advancing radiation therapy for cancer treatment and is headquartered in Madison, Wisconsin.
Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026
Accuray Incorporated will report its financial results for the second quarter of fiscal year 2026, which ended December 31, 2025, on February 4, 2026. A conference call hosted by company management will take place at 1:30 p.m. PT/4:30 p.m. ET on that date to discuss the results. A live webcast and replay of the call will be available on the company's investor relations website for those unable to attend.
Following a 59% decline over last year, recent gains may please Accuray Incorporated (NASDAQ:ARAY) institutional owners
Institutional investors hold a significant 59% stake in Accuray Incorporated (NASDAQ:ARAY), meaning their trading decisions heavily influence the stock. After experiencing a 59% loss over the past year, these institutional owners are likely pleased with the recent 11% increase in share price. BlackRock, Inc., The Vanguard Group, Inc., and Aevum Pension Fund are among the top shareholders, while company insiders also own a small but notable portion of the stock.
Following a 59% decline over last year, recent gains may please Accuray Incorporated (NASDAQ:ARAY) institutional owners
Accuray Incorporated has seen a 59% decline over the last year, but a recent 11% increase in share price may be welcome news to its institutional owners, who collectively hold 59% of the company. Key institutional investors include BlackRock, Inc., The Vanguard Group, Inc., and Aevum Pension Fund, while company insiders own US$4.8 million worth of stock, and the general public holds a 36% stake. The article suggests that while institutional ownership provides credibility, investors should also consider analyst sentiments and other financial factors.
Following a 59% decline over last year, recent gains may please Accuray Incorporated (NASDAQ:ARAY) institutional owners
Institutional investors, holding 59% of Accuray Incorporated (NASDAQ:ARAY), may be encouraged by a recent 11% share price increase after a year-long 59% decline. BlackRock, Inc. is the largest shareholder with 7.7%, and insiders collectively own US$4.8 million worth of stock. The general public maintains a 36% stake in the company.
Accuray (NASDAQ:ARAY) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen has upgraded Accuray (NASDAQ:ARAY) from a "sell" to a "hold" rating, aligning with the stock's current consensus "Hold" rating and an average price target of $4.00. Despite missing quarterly EPS estimates with a loss of ($0.18) per share, the medical equipment provider slightly exceeded revenue expectations. Accuray, trading around $0.85 with a $96 million market cap and negative profitability metrics, has significant institutional ownership at approximately 64%.
Accuray director Byron C. Scott to retire from board at year-end
Accuray (NASDAQ:ARAY) director Byron C. Scott is retiring from the board, effective December 31, 2025, a decision not related to company disagreements. This follows Accuray's Q1 FY2026 results, which showed a larger-than-expected loss but a revenue beat, alongside a strategic transformation plan to improve profitability and a 15% workforce reduction. BTIG has lowered its price target for Accuray to $4.00, maintaining a Buy rating amidst these developments.
Accuray Incorporated Announces Retirement of Byron C. Scott as Class III Director and Including All Committees, Effective December 31, 2025
Accuray Incorporated announced that Byron C. Scott will retire from its Board of Directors, including all committees, effective December 31, 2025. This decision was not due to any disagreements with the company, its Board, operations, policies, or practices. Mr. Scott served as a Class II director of Accuray.
Accuray Incorporated's (NASDAQ:ARAY) 25% Dip In Price Shows Sentiment Is Matching Revenues
Accuray Incorporated (NASDAQ:ARAY) has experienced a significant 25% drop in its share price over the last month, culminating in a 59% decline over the past year. This poor performance is attributed to sluggish revenue growth compared to competitors in the Medical Equipment industry. The company's low price-to-sales (P/S) ratio of 0.2x reflects investor pessimism, especially given that future revenue growth is projected to be 4.6%, far below the industry forecast of 48%.
